Impact News +++ Oracle Surges 7% as AI Cloud Backlog Hits $664B, CoreWeave and Nebius Climb 4% (24/7 Wall St.) +++ ORACLE Aktie -4,63%

IPSEN Aktie

>IPSEN Aktienkurs

157.4 EUR +0.8% (TradegateBSX)

Ask: 157.8 EUR / 31 Stück

Bid: 157.5 EUR / 31 Stück

Tagesumsatz: 31 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

IPSEN Aktie über LYNX handeln

Intraday

1 Jahr

>IPSEN Performance

1 Woche: -6,8%

1 Monat: -1,9%

3 Monate: +1,7%

6 Monate: -1,4%

1 Jahr: +33,6%

laufendes Jahr: +30,9%

>IPSEN Aktie

Profil:

Ipsen S.A. is a French biopharmaceutical company headquartered in Paris, specializing in the development and commercialization of transformative medicines across three core therapeutic areas: oncology, rare diseases, and neuroscience. Founded in 1929..
>Volltext..

Insiderhandel:

>IPSEN Kennzahlen

Aktien/ Unternehmen:

Analysten:

Bewertung:

Rentabilität:

Managementeffizenz:

>IPSEN Peer Group

Gesundheit, Lebererkrankungen & -behandlung/ Hepatitis, Zell- & Gentherapie/ Gentechnik/ Erbkrankheiten, Neurologische Erkrankungen/ Schlaganfälle, Onkologie/ Krebs- Behandlung
>Alle Branchen..

>IPSEN Chart & Kurs - Tradegate

>IPSEN News

11.09.26 - 12:00	Ipsen Weighs U.S. Manufacturing Investment (WSJ EN)
	The French drugmaker is considering building a U.S. production site, joining other European companies looking across the pond when planning new investments....

08.09.26 - 13:12	Ipsen Aktie unter Druck: Barclays-Herabstufung schürt Sorgen um Gewinnentwicklung (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

04.08.26 - 13:01	Marengo Nominates First Drug Candidate Under Strategic TriSTAR Collaboration with Ipsen and Welcomes Industry-Leading T-Cell Engager Expert, Saso Cemerski, Ph.D., to Accelerate Pipeline Expansion (PR Newswire)
	First partnered TriSTAR program advances into IND-enabling development Industry-leading expert in T-cell engager discovery and immune-cell activation, Saso Cemerski, joins as Senior Vice President, Head of Immunology, to accelerate expansion of Marengo's precision Vβ-directed T-cell......

03.08.26 - 18:03	IPSEN - Buy-back programme - Art 5 of MAR - Week 31 - 2026 (GlobeNewswire EN)
	Aggregated presentation by day and by market...

03.08.26 - 14:31	Jefferies cuts Ipsen on Camurus competition risk (Investing.com)
	Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

30.07.26 - 18:06	Ipsen S.A. publishes its 2026 Half-Year Report (half-year ended 30 June 2026) (GlobeNewswire EN)
	Ipsen S.A. publishes its 2026 Half-Year Report (half-year ended 30 June 2026)...

30.07.26 - 12:45	Ipsen slips despite raising outlook on broad-based drug sales growth (Investing.com)
	Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

30.07.26 - 07:48	Ipsen S.A. Non-GAAP EPS of €7.33, revenue of €2.19B; upgrades FY 2026 financial guidance (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

30.07.26 - 07:30	Ipsen hebt Prognose für 2026 nach Umsatzsprung im ersten Halbjahr an (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

30.07.26 - 07:03	Ipsen delivers excellent H1 2026 results and upgrades its full-year guidance (GlobeNewswire EN)
	PARIS, FRANCE, 30 July 2026 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its financial results for the first half of 2026....

29.07.26 - 19:03	Ipsen nominates Catherine Bradley to its Board of Directors as independent Director (GlobeNewswire EN)
	Ipsen appoints Catherine Bradley as independent Director to its Board of Directors...

27.07.26 - 18:03	IPSEN - Buy-back programme - Art 5 of MAR - Week 30 - 2026 (GlobeNewswire EN)
	Aggregated presentation by day and by market...

24.07.26 - 16:06	Ipsen phase 3 Bylvay trial in biliary atresia misses primary goal (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

24.07.26 - 13:54	Health Care Roundup: Market Talk (WSJ EN)
	Find insight on Roche Holding, CSL, and Ipsen in the latest Market Talks covering Health Care....

24.07.26 - 09:30	Ipsen Drug Misses Goal in Late-Stage Trial for Rare Liver Disease (WSJ EN)
	Bylvay missed the study's primary objective of showing an improvement in native liver survival rates compared to placebo....

24.07.26 - 07:03

Ipsen provides update on Phase III BOLD trial in biliary atresia (GlobeNewswire EN)

PARIS, FRANCE, 24 JULY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Phase III BOLD trial evaluating Bylvay versus placebo for patients living with biliary atresia (BA) who have already undergone a Kasai hepatoportoenterostomy (HPE) did not meet the primary endpoint of improvement in native liver survival vs placebo. Current topline data is in line with the well-established safety profile of odevixibat in approved indications. Characterized as a rapidly progressive and complex condition, BA is the leading cause of paediatric liver transplant, with no approved therapeutic options beyond Kasai HPE or liver transplant surgery....

22.07.26 - 18:03	Ipsen - Corrective statement amending the monthly disclosure of the total number of shares and voting rights as of June 30, 2026 (GlobeNewswire EN)
	CORRECTIVE STATEMENT...

22.07.26 - 07:03	Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset to Ipsen′s Rare Disease pipeline (GlobeNewswire EN)
	PARIS, FRANCE, 22 JULY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today it has completed the acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, an anti-BK polyomavirus monoclonal antibody....

21.07.26 - 18:03	IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2026 (GlobeNewswire EN)
	Aggregated presentation by day and by market...

15.07.26 - 18:03	IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2026 (GlobeNewswire EN)
	Aggregated presentation by day and by market...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Werturteile sind nie Wahrheiten, sondern Wünsche, die meist erst wahr gemacht werden sollen. - Ludwig Marcuse

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram